Avanos Medical, Inc. (NYSE: AVNS) reported Q3 EPS of $0.30, $0.02 better than the analyst estimate of $0.28. Revenue for the quarter came in at $171.3 million versus the consensus estimate of $169.6 million.

GUIDANCE:

Avanos Medical, Inc. sees FY2023 EPS of $1.05-$1.15, versus the consensus of $1.09.

For earnings history and earnings-related data on Avanos Medical, Inc. (AVNS) click here.